Cross-posted from the HHS.gov Hepatitis blog

The National Institutes of Health (NIH) recently announced a cooperative agreement opportunity to encourage the development of vaccines against the hepatitis C virus (HCV). The purpose of this Funding Opportunity Announcement (FOA) is:

  • to support novel strategies for the rational design of vaccines against HCV,
  • to assess the vaccines for their ability to induce protective immune responses, and
  • to select candidates for preclinical development and clinical testing.

To accomplish this, it will be critical to advance knowledge of the structural basis for broad immunological protection and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This information will serve as a guide for the construction of new and improved candidate prophylactic HCV vaccines that will be assessed for immunogenicity and efficacy in appropriate animal models.

The closing date for this FOA is June 15, 2020. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

For more information, visit http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-019.html.

Related pages and posts: